Fig. 5From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a studyMagnitude of impairment on individual neuropsychological tests at baseline assessment (Cogstate). Impairment defined as group mean performance expressed standardized score (z) using age-matched normative data (mean and SD). ISLT International Shopping List Task, OCL One Card LearningBack to article page